Neurogene (NGNE) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Neurogene (NGNE) has outperformed Rezolute (RZLT) over the past year, losing 16.3% versus a loss of 44.8%. Over five years, RZLT leads with a -26.8% price change compared with -81.7% for NGNE. Neurogene is the larger company by market cap ($528.3 million vs $471.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGNE | RZLT |
|---|---|---|
| Share price | $26.40 | $4.87 |
| Market cap | $528.30M | $471.04M |
| 1-day change | -0.38% | +4.96% |
| YTD return | +28.16% | +106.36% |
| 1-year return | -16.35% | -44.85% |
| 5-year return | -81.72% | -26.77% |
| EPS (TTM) | $-5.04 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.66 | $11.46 |
| 52-week low | $15.93 | $1.07 |
| Distance from 52-week high | -39.53% | -57.49% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +195.00% | +101.23% |
| Average volume | 246.44K | 1.48M |
| Shares outstanding | 20.01M | 96.72M |
| Employees | 131 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed RZLT by 28.5 percentage points over the past year.
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
NGNE vs RZLT FAQ
Which is bigger, Neurogene or Rezolute?
Neurogene (NGNE) is larger, with a market capitalization of $528.30M compared with $471.04M for Rezolute (RZLT).
Which stock has performed better over the past year, NGNE or RZLT?
NGNE returned -16.35% over the past 12 months, compared with -44.85% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Neurogene and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.